References
- Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663–70
- Mentlein R. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9–24
- Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199–E206
- Mari A, Sallas WM, He YL, . Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888–94
- Ahren B, Landin-Olsson M, Jansson PA, . Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078–84
- Pratley RE, Jauffret-Kamel S, Galbreath E, . Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423–8
- Ristic S, Byiers S, Foley J, . Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692–8
- Nathan DM, Buse JB, Davidson MB, . Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–21
- Turner RC, Cull CA, Frighi V, . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999; 281: 2005–12
- Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63: 1879–94
- Bosi E, Camisasca RP, Collober C, . Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890–5
- Sambol NC, Brookes LG, Chiang J, . Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996; 42: 510–12
- Sunkara G, Sabo R, Wang Y, . Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007; 47: 1152–8
- He YL, Sabo R, Picard F, . Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ther 2006; 79: P62
- Marathe PH, Arnold ME, Meeker J, . Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol 2000; 40: 1494–502
- Karim A, Slater M, Bradford D, . Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. J Clin Pharmacol 2007; 47: 48–55
- Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37: 213–55
- Cheng C, Yu L, Lee H, . Biowaver extension potential to BCS Class III high solubility–low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 2004; 22: 297–304
- Amidon GL, Lennernas H, Shah VP, . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413–20
- Glucophage Prescribing Information. Princeton, NJ, USA: Bristol-Myers Squibb Company. Revised June 2006
- Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721–49
- Pi-Sunyer FX, Schweizer A, Mills D, . Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132–8